Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.

Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, Lerner A, Tabaton M, Perry G, Smith MA. Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study. Exp Gerontol. 2010 Jan; 45(1):47-52.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Alzheimer Disease
Antigen-Antibody Complex
Autoantibodies
Disease Progression
Early Diagnosis
Enzyme-Linked Immunosorbent Assay
Humans
Middle Aged
Risk Factors
Sensitivity and Specificity
Seroepidemiologic Studies

authors with profiles

George Perry

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support